Sverre Erik Kjeldsen

• Mancia, Giuseppe; Brunström, Mattias; Burnier, Michel; Grassi, Guido; Januszewicz, Andrzej & Kjeldsen, Sverre [Show all 10 contributors for this article] (2024). Rationale for the Inclusion of β-Blockers among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension. ISSN 0194-911X. 81(5), p. 1021–1030. doi: 10.1161/HYPERTENSIONAHA.124.22821.
• Fadl Elmula, Fadl Elmula M.; Mariampillai, Julian Eek; Heimark, Sondre; Kjeldsen, Sverre & Burnier, Michel (2024). Medical Measures in Hypertensives Considered Resistant. American Journal of Hypertension. ISSN 0895-7061. 37(5), p. 307–317. doi: 10.1093/ajh/hpad118.
• Mancia, Giuseppe; Brunström, Mattias; Burnier, Michel; Grassi, Guido; Januszewicz, Andrzej & Muiesan, Maria Lorenza [Show all 9 contributors for this article] (2024). Rationale of treatment recommendations in the 2023 ESH hypertension guidelines. European journal of internal medicine. ISSN 0953-6205. doi: 10.1016/j.ejim.2023.12.015.
• Sevre, Kaja; Rist, Aurora; Wachtell, Kristian; Devereux, Richard B.; Aurigemma, Gerard P. & Smiseth, Otto Armin [Show all 14 contributors for this article] (2024). What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence. American Journal of Hypertension. ISSN 0895-7061. 37(1), p. 1–14. doi: 10.1093/ajh/hpad073.
• Persu, Alexandre; Stoenoiu, Maria S.; Maes, Frédéric; Kreutz, Reinhold; Mancia, Giuseppe & Kjeldsen, Sverre (2023). Late outcomes of renal denervation are more favourable than early ones: facts or fancies. Clinical Kidney Journal (CKJ). ISSN 2048-8505. 16(12), p. 2357–2364. doi: 10.1093/ckj/sfad231. Full text in Research Archive
• Burnier, Michel; Narkiewicz, Krzysztof & Kjeldsen, Sverre (2023). How to optimize the use of diuretics in patients with heart failure? Kardiologia polska. ISSN 0022-9032. 81(10), p. 944–949. doi: 10.33963/v.kp.97315. Full text in Research Archive
• Mancia, Giuseppe; Kreutz, Reinhold; Brunström, Mattias; Burnier, Michel; Grassi, Guido & Januszewicz, Andrzej [Show all 59 contributors for this article] (2023). 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension. ISSN 0263-6352. 41(12), p. 1874–2071. doi: 10.1097/HJH.0000000000003480.
• Rist, Aurora; Wachtell, Kristian; Holter Sevre, Kaja; Devereux, Richard B.; Aurigemma, Gerard P. & Smiseth, Otto Armin [Show all 14 contributors for this article] (2023). The current best drug treatment for hypertensive heart failure with preserved ejection fraction. European journal of internal medicine. ISSN 0953-6205. doi: 10.1016/j.ejim.2023.10.008. Full text in Research Archive
• Feinberg, Joshua B; Nielsen, Emil E; Kjeldsen, Sverre; Devereux, Richard B; Gerdts, Eva & Wachtell, Kristian [Show all 7 contributors for this article] (2023). Sex Differences in Atrial Fibrillation and Associated Complications in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study. American Journal of Hypertension. ISSN 0895-7061. 36(10), p. 536–541. doi: 10.1093/ajh/hpad057.
• Heimark, Sondre; Mehlum, Maria Hollund; Mancia, Giuseppe; Søraas, Camilla Lund; Liestøl, Knut & Wachtell, Kristian [Show all 12 contributors for this article] (2023). Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg. Hypertension. ISSN 0194-911X. 80(8), p. 1739–1748. doi: 10.1161/HYPERTENSIONAHA.123.21454.
• Brunström, Mattias; Carlberg, Bo & Kjeldsen, Sverre (2023). Effect of antihypertensive treatment in isolated systolic hypertension (ISH)–systematic review and meta-analysis of randomised controlled trials. Blood Pressure. ISSN 0803-7051. 32(1). doi: 10.1080/08037051.2023.2226757. Full text in Research Archive
• Halvorsen, Lene Vernås; Bergland, Ola Undrum; Søraas, Camilla Lund; Larstorp, Anne Cecilie Kjeldsen; Hjørnholm, Ulla & Kjær, Vibeke Norheim [Show all 14 contributors for this article] (2022). Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7-Year Follow-Up of Patients Considered Adherent by Directly Observed Therapy. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 11(18). doi: 10.1161/JAHA.121.025879. Full text in Research Archive Show summary

  Background Measurement of serum concentrations of drugs is a novelty found useful in detecting poor drug adherence in patients taking ≥2 antihypertensive agents. Regarding patients with treatment‐resistant hypertension, we previously based our assessment on directly observed therapy. The present study aimed to investigate whether serum drug measurements in patients with resistant hypertension offer additional information regarding drug adherence, beyond that of initial assessment with directly observed therapy. Methods and Results Nineteen patients assumed to have true treatment‐resistant hypertension and adherence to antihypertensive drugs based on directly observed therapy were investigated repeatedly through 7 years. Serum concentrations of antihypertensive drugs were measured by ultra‐high‐performance liquid chromatography–tandem mass spectrometry from blood samples taken at baseline, 6‐month, 3‐year, and 7‐year visits. Cytochrome P450 polymorphisms, self‐reported adherence and beliefs about medicine were performed as supplement investigations. Seven patients (37%) were redefined as nonadherent based on their serum concentrations during follow‐up. All patients reported high adherence to medications. Nonadherent patients expressed lower necessity and higher concerns regarding intake of antihypertensive medication (P=0.003). Cytochrome P450 polymorphisms affecting metabolism of antihypertensive drugs were found in 16 patients (84%), 21% were poor metabolizers, and none were ultra‐rapid metabolizers. Six of 7 patients redefined as nonadherent had cytochrome P450 polymorphisms, however, not explaining the low serum drug concentrations measured in these patients. Conclusions Our data suggest that repeated measurements of serum concentrations of antihypertensive drugs revealed nonadherence in one‐third of patients previously evaluated as adherent and treatment resistant by directly observed therapy, thereby improving the accuracy of adherence evaluation. Registration URL: https://www.clinicaltrials.gov; unique identifier: NCT01673516.

• Messerli, Franz H.; Bavishi, Chirag; Brguljan, Jana; Burnier, Michel; Dobner, Stephan & Elijovich, Fernando [Show all 21 contributors for this article] (2022). Renal denervation in the antihypertensive arsenal - knowns and known unknowns. Journal of Hypertension. ISSN 0263-6352. 40(10), p. 1859–1875. doi: 10.1097/HJH.0000000000003171.
• Mancia, Giuseppe; Kjeldsen, Sverre; Kreutz, Reinhold; Pathak, Atul; Grassi, Guido & Esler, Murray (2022). Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension. ISSN 0194-911X. 79(6), p. 1153–1166. doi: 10.1161/HYPERTENSIONAHA.122.19020.
• Bang, Casper N.; Greve, Anders M.; Køber, Lars; Muthiah, Anujan; Kjeldsen, Sverre & Julius, Stevo [Show all 9 contributors for this article] (2022). Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of medicine. ISSN 2692-3106. doi: 10.37349/emed.2022.00080.
• Chinali, Marcello; Aurigemma, Gerard P.; Gerdts, Eva; Wachtell, Kristian; Okin, Peter M. & Muthiah, Anujan [Show all 10 contributors for this article] (2022). Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of medicine. ISSN 2692-3106. 3, p. 160–172. doi: 10.37349/emed.2022.00082.
• Zacks, Eran S.; Stokke, Ildri Maria; Wachtell, Kristian; Hille, Darcy A.; Høieggen, Aud & Kjeldsen, Sverre [Show all 10 contributors for this article] (2022). Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. Exploration of medicine. ISSN 2692-3106. 3(2), p. 128–138. doi: 10.37349/emed.2022.00079.
• Bang, Casper N.; Li, Zhibin; Stokke, Ildri Maria; Kjeldsen, Sverre; Julius, Stevo & Hille, Darcy A. [Show all 9 contributors for this article] (2022). Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. Exploration of medicine. ISSN 2692-3106. 2022(3), p. 149–159. doi: 10.37349/emed.2022.00081.
• Esler, Murray; Kjeldsen, Sverre; Pathak, Atul; Grassi, Guido; Kreutz, Reinhold & Mancia, Giuseppe (2022). Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. Blood Pressure. ISSN 0803-7051. 31(1), p. 210–224. doi: 10.1080/08037051.2022.2110858. Full text in Research Archive
• Lilja-Cyron, Alexander; Bang, Casper N.; Gerdts, Eva; Larstorp, Anne Cecilie Kjeldsen; Kjeldsen, Sverre & Julius, Stevo [Show all 9 contributors for this article] (2022). Aortic root dilatation in hypertensive patients with left ventricular hypertrophy–application of a new multivariate predictive model. The Life Study. Reviews in Cardiovascular Medicine (RCM). ISSN 1530-6550. 23(3), p. 1–10. doi: 10.31083/j.rcm2303095. Full text in Research Archive Show summary

  Background: Available nomograms to predict aortic root (AoR) diameter for body surface area have limitations. The purpose of this study was to evaluate the use of a new multivariate predictive model to identify AoR dilatation in hypertensive patients with left ventricular hypertrophy. Methods: 943 of 961 patients in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiographic sub-study had the necessary baseline characteristics and echocardiographic 2D measurements of AoR size to be included. Results: Predicted AoR (Sinus of Valsalva) diameter was 1.519 + (age [years] × 0.010) + (height [cm] × 0.010) – (gender [1 = M, 2 = F] × 0.247), and a measured AoR diameter exceeding the 97.5-percentile of this estimate was considered dilated. Measured AoR diameter was larger in men than in women (3.75 vs. 3.48 cm, p < 0.001) and AoR diameter predicted by the model was larger than predicted by nomogram (3.52 vs. 3.28 cm, p < 0.001). Using the multivariate model to identify patients with AoR dilatation, the prevalence was 13.7% in men and 12.3% in women (p = 0.537). There was consensus of AoR phenotype (normal/dilated) between model and nomogram in 92.8% of the patients. In multivariate logistic regression, AoR dilatation by model definition was predicted by presence of aortic regurgitation (OR 2.67, p < 0.001) and SD increase in age (OR 0.75, p = 0.023), pulse pressure (OR 0.64, p < 0.001), left ventricular mass index (OR 1.36, p = 0.08) and stroke volume (OR 1.45, p = 0.002), but not by body weight. Conclusions: Using the proposed model the prevalence of AoR dilatation was equal in men and women and the model seems to address the effects of gender, age and body size on AoR size.

• Brunström, Mattias; Kjeldsen, Sverre; Kreutz, Reinhold; Gjesdal, Knut Tjøl; Narkiewicz, Krzysztof & Burnier, Michel [Show all 8 contributors for this article] (2021). Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. Hypertension. ISSN 0194-911X. 78(2), p. 555–558. doi: 10.1161/HYPERTENSIONAHA.121.17356.
• Copland, Emma; Canoy, Dexter; Nazarzadeh, Milad; Bidel, Zeinab; Ramakrishnan, Rema & Woodward, Mark [Show all 99 contributors for this article] (2021). Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. The Lancet Oncology. ISSN 1470-2045. 22(4), p. 558–570. doi: 10.1016/S1470-2045(21)00033-4.
• Bergland, Ola Undrum; Halvorsen, Lene Vernås; Søraas, Camilla Lund; Hjørnholm, Ulla; Kjær, Vibeke Norheim & Rognstad, Stine [Show all 22 contributors for this article] (2021). Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations. Hypertension. ISSN 0194-911X. 78(3), p. 617–628. doi: 10.1161/HYPERTENSIONAHA.121.17514. Full text in Research Archive Show summary

  Nonadherence to drugs is a challenge in hypertension treatment. We aimed to assess the prevalence of nonadherence by serum drug concentrations compared with 2 indirect methods and relate to the prescribed drug regimens in a nationwide multicenter study. Five hundred fifty patients with hypertension using ≥2 antihypertensive agents participated. We measured concentrations of 23 antihypertensive drugs using ultra high performance liquid chromatography tandem mass-spectrometry and compared with patients’ self-reports and investigators’ assessment based on structured interview. We identified 40 nonadherent patients (7.3%) using serum drug concentrations. They had higher office diastolic blood pressure (90 versus 83 mm Hg, P<0.01) and daytime diastolic blood pressure (85 versus 80 mm Hg, P<0.01) though systolic blood pressures did not differ significantly. They had more prescribed daily antihypertensive pills (2.5 versus 2.1 pills, P<0.01) and total daily pills (5.5 versus 4.4 pills, P=0.03). Prescription of fixed-dose combination pills were lower among the nonadherent patients identified by serum concentrations (45.0 versus 67.1%, P<0.01). Fifty-three patients self-reported nonadherence, while the investigators suspected 69 nonadherent patients. These groups showed no or few differences in drug regimens, respectively. In summary, we detected 7.3% prevalence of nonadherence by serum drug measurements in patients using ≥2 antihypertensive agents in a nationwide study; they had higher office and ambulatory diastolic blood pressures, higher number of prescribed daily pills, more daily antihypertensive pills, and less frequent prescriptions of fixed-dose combination pills. Indirect methods showed poor overlap with serum drugs concentrations and no or minimal medication differences. Thus, serum measurements of drugs were useful in detection and characterization of nonadherence to antihypertensive treatment.

• Kasiakogias, Alexandros; Rosei, Enrico Agabiti; Camafort, Miguel; Ehret, Georg; Faconti, Luca & Ferreira, João Pedro [Show all 19 contributors for this article] (2021). Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension. ISSN 0263-6352. 39(8), p. 1522–1545. doi: 10.1097/HJH.0000000000002910. Full text in Research Archive
• Falk, Ragnhild Sørum; Mariampillai, Julian Eek; Prestgaard, Erik Edvard; Heir, Trond; Bodegard, Johan & Robsahm, Trude Eid [Show all 18 contributors for this article] (2021). The Oslo Ischaemia Study: cohort profile. BMJ Open. ISSN 2044-6055. 11(10). doi: 10.1136/bmjopen-2021-049111. Full text in Research Archive Show summary

  Abstract Purpose The Oslo Ischaemia Study was designed to investigate the prevalence and predictors of silent coronary disease in Norwegian middle-aged men, specifically validating exercise electrocardiography (ECG) findings compared with angiography. The study has been important in investigating long-term predictors of cardiovascular morbidity and mortality, as well as investigating a broad spectrum of epidemiological and public health perspectives. Participants In 1972–1975, 2014 healthy men, 40–59 years old, were enrolled in the study. Comprehensive clinical examination included an ECG-monitored exercise test at baseline and follow-ups. The cohort has been re-examined four times during 20 years. Linkage to health records and national health registries has ensured complete endpoint registration of morbidity until the end of 2006, and cancer and mortality until the end of 2017. Findings to date The early study results provided new evidence, as many participants with a positive exercise ECG, but no chest pain (‘silent ischaemia’), did not have significant coronary artery stenosis after all. Still, they were over-represented with coronary disease after years of follow-up. Furthermore, participants with the highest physical fitness had lower risk of cardiovascular disease, and the magnitude of blood pressure responses to moderate exercise was shown to influence the risk of cardiovascular disease and mortality. With time, follow-up data allowed the scope of research to expand into other fields of medicine, with the aim of investigating predictors and the importance of lifestyle and risk factors. Future plans Recently, the Oslo Ischaemia Study has been found worthy, as the first scientific study, to be preserved by The National Archives of Norway. All the study material will be digitised, free to use and accessible for all. In 2030, the Oslo Ischaemia Study will be linked to the Norwegian Cause of Death Registry to obtain complete follow-up to death. Thus, a broad spectrum of additional opportunities opens.

• Mariampillai, Julian Eek; Prestgaard, Erik Edvard; Kjeldsen, Sverre; Liestøl, Knut; Grundvold, Irene & Bodegard, Johan [Show all 9 contributors for this article] (2021). Novel insights into stroke risk beyond resting and maximal bicycle exercise systolic blood pressure. Journal of Hypertension. ISSN 0263-6352. 39(10), p. 2022–2029. doi: 10.1097/HJH.0000000000002894.
• Parati, Gianfranco; Kjeldsen, Sverre; Coca, Antonio; Cushman, William C. & Wang, Jiguang (2021). Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. ISSN 0194-911X. 77(2), p. 692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781. Full text in Research Archive
• Olsen, Eirik; Holzhauer, Björn; Julius, Stevo; Kjeldsen, Sverre; Larstorp, Anne Cecilie Kjeldsen & Mancia, Giuseppe [Show all 12 contributors for this article] (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk. Blood Pressure. ISSN 0803-7051. 30. doi: 10.1080/08037051.2020.1856642. Full text in Research Archive
• Olsen, Eirik; Holzhauer, Björn; Julius, Stevo; Kjeldsen, Sverre; Larstorp, Anne Cecilie Kjeldsen & Mancia, Giuseppe [Show all 12 contributors for this article] (2021). Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Pressure. ISSN 0803-7051. doi: 10.1080/08037051.2020.1855968. Full text in Research Archive
• Kjeldsen, Sverre & Os, Ingrid (2020). Assessing hypertension therapies: randomization or confounding by indication? Nature Reviews Cardiology. ISSN 1759-5002. 17(2), p. 73–74. doi: 10.1038/s41569-019-0313-z.
• Mahfoud, Felix; Azizi, Michel; Ewen, Sebastian; Pathak, Atul; Ukena, Christian & Blankestijn, Peter J [Show all 31 contributors for this article] (2020). Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. European Heart Journal. ISSN 0195-668X. 41(16), p. 1588–1599. doi: 10.1093/eurheartj/ehaa121.
• Burnier, Michel; Kreutz, Reinhold; Narkiewicz, Krzysztof; Kjeldsen, Sverre; Oparil, Suzanne & Mancia, Giuseppe (2020). Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: Is dosing in the evening better than in the morning? Journal of Hypertension. ISSN 0263-6352. 38(8), p. 1396–1406. doi: 10.1097/HJH.0000000000002532.
• Mehlum, Maria Hollund; Liestøl, Knut; Kjeldsen, Sverre; Wyller, Torgeir Bruun; Julius, Stevo & Rothwell, Peter M. [Show all 10 contributors for this article] (2020). Blood pressure-lowering profiles and clinical effects of angiotensin receptor blockers versus calcium channel blockers. Hypertension. ISSN 0194-911X. 75(6), p. 1584–1592. doi: 10.1161/HYPERTENSIONAHA.119.14443.
• Prestgaard, Erik Edvard; Mariampillai, Julian Eek; Engeseth, Kristian; Erikssen, Jan Emil; Bodegard, Johan & Liestøl, Knut [Show all 9 contributors for this article] (2020). Change in body weight and long-term risk of stroke and death in healthy men. Stroke. ISSN 0039-2499. 51(5), p. 1435–1441. doi: 10.1161/STROKEAHA.119.027233.
• Mirza, Yusuf Ahmed; Prestgaard, Erik Edvard; Selmer, Randi Marie; Liestøl, Knut; Grundvold, Irene & Erikssen, Jan Emil [Show all 8 contributors for this article] (2020). Tiårsprediksjon av hjerte-og karsykdom hos friske norske menn basert på NORRISK-2. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 140(12), p. 1–10. doi: 10.4045/tidsskr.20.0089. Full text in Research Archive
• Kjeldsen, Sverre; Halvorsen, Sigrun; Wyller, Torgeir Bruun; Bath, Philip M. & Sandercock, Peter (2020). Eivind Berge, MD, PhD, 1964-2020: Cardiologist Who Was Fighting Stroke. Stroke. ISSN 0039-2499. 51(5), p. 1353–1355. doi: 10.1161/STROKEAHA.120.029351.
• Willeit, Peter; Tschiderer, Lena; Allara, Elias; Reuber, Kathrin; Seekircher, Lisa & Gao, Lu [Show all 76 contributors for this article] (2020). Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk : Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation. ISSN 0009-7322. 142(7), p. 621–642. doi: 10.1161/CIRCULATIONAHA.120.046361. Show summary

  Background: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk. Methods: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-artery; if unavailable, the maximum value at the common-carotid-artery or other cIMT measures were used. The primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. We estimated intervention effects on cIMT progression and incident CVD for each trial, before relating the 2 using a Bayesian meta-regression approach. Results: We analyzed data of 119 randomized, controlled trials involving 100 667 patients (mean age 62 years, 42% female). Over an average follow-up of 3.7 years, 12 038 patients developed the combined CVD end point. Across all interventions, each 10 μm/y reduction of cIMT progression resulted in a relative risk for CVD of 0.91 (95% Credible Interval, 0.87–0.94), with an additional relative risk for CVD of 0.92 (0.87–0.97) being achieved independent of cIMT progression. Taken together, we estimated that interventions reducing cIMT progression by 10, 20, 30, or 40 μm/y would yield relative risks of 0.84 (0.75–0.93), 0.76 (0.67–0.85), 0.69 (0.59–0.79), or 0.63 (0.52–0.74), respectively. Results were similar when grouping trials by type of intervention, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurement, and proportion of female patients. Conclusions: The extent of intervention effects on cIMT progression predicted the degree of CVD risk reduction. This provides a missing link supporting the usefulness of cIMT progression as a surrogate marker for CVD risk in clinical trials.

• Holanger, Magnus; Kjeldsen, Sverre; Jamerson, Kenneth & Julius, Stevo (2020). Smoking and overweight associated with masked uncontrolled hypertension: a Hypertension Optimal Treatment (HOT) Sub-Study. Blood Pressure. ISSN 0803-7051. p. 1–9. doi: 10.1080/08037051.2020.1787815. Full text in Research Archive
• Okin, Peter M.; Hille, Darcy A.; Wachtell, Kristian; Kjeldsen, Sverre Erik; Julius, Stevo & Devereux, Richard B. (2020). On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Blood Pressure. ISSN 0803-7051. 29(5), p. 319–326. doi: 10.1080/08037051.2020.1782171. Full text in Research Archive
• Kjeldsen, Sverre; von Lueder, Thomas Gero; Smiseth, Otto A.; Wachtell, Kristian; Mistry, Nisha & Westheim, Arne [Show all 12 contributors for this article] (2019). Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension. ISSN 0194-911X. doi: 10.1161/HYPERTENSIONAHA.119.14057. Full text in Research Archive
• Mariampillai, Julian Eek; Liestøl, Knut; Kjeldsen, Sverre; Prestgaard, Erik Edvard; Engeseth, Kristian & Bodegard, Johan [Show all 11 contributors for this article] (2019). Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy Men. Hypertension Research. ISSN 0916-9636. 75(1), p. 44–50. doi: 10.1161/HYPERTENSIONAHA.119.13528. Full text in Research Archive
• Egan, Brent M; Kjeldsen, Sverre; Grassi, Guido; Esler, Murray D. & Mancia, Giuseppe (2019). The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? Journal of Hypertension. ISSN 0263-6352. 37(6), p. 1148–1153. doi: 10.1097/HJH.0000000000002021. Full text in Research Archive
• Larstorp, Anne Cecilie Kjeldsen; Stokke, Ildri Maria; Kjeldsen, Sverre; Hecht Olsen, Michael; Okin, Peter M. & Devereux, Richard B [Show all 7 contributors for this article] (2019). Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. Blood Pressure. ISSN 0803-7051. 28(5), p. 317–326. doi: 10.1080/08037051.2019.1633905. Full text in Research Archive
• Kjeldsen, Sverre; Aksnes, Tonje Amb; Mo, Rune & Klemsdal, Tor Ole (2019). Impact of the new ACC/AHA and ESC/ESH hypertension guidelines for Norway. European Heart Journal. ISSN 0195-668X. 40(19), p. 1485–1487. doi: 10.1093/eurheartj/ehz266.
• Kjeldsen, Sverre; Os, Ingrid & Westheim, Anne (2019). Could adverse events offset the benefit of intensive blood pressure lowering treatment in the Systolic Blood Pressure Intervention Trial? Journal of Hypertension. ISSN 0263-6352. 37(5), p. 902–904. doi: 10.1097/HJH.0000000000002018.
• Smiseth, Otto A.; Kjeldsen, Sverre; Andersen, Øyvind Senstad; Mistry, Nisha; Westheim, Arne & Skulstad, Helge [Show all 7 contributors for this article] (2019). Hjertesvikt med normal ejeksjonsfraksjon. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 139(6), p. 522–527. doi: 10.4045/tidsskr.18.0523.
• Okin, Peter M.; Kjeldsen, Sverre & Devereux, Richard B (2019). Effect of antihypertensive therapy on development of incident conduction system disease in hypertensive patients. Journal of Hypertension. ISSN 0263-6352. 37(3), p. 629–635. doi: 10.1097/HJH.0000000000001915.
• Stokke, Ildri Maria; Li, Zhi Bin; Cicala, Silvana; Okin, Peter M.; Kjeldsen, Sverre & Devereux, Richard B [Show all 7 contributors for this article] (2019). Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study. Blood Pressure. ISSN 0803-7051. 28(2), p. 84–92. doi: 10.1080/08037051.2019.1569463. Full text in Research Archive
• Mariampillai, Julian Eek; Prestgaard, Erik Edvard; Kjeldsen, Sverre; Liestøl, Knut; Engeseth, Kristian & Erikssen, Jan Emil [Show all 10 contributors for this article] (2019). SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-up. Journal of Hypertension. ISSN 0263-6352. 37(5), p. 949–955. doi: 10.1097/HJH.0000000000001959.
• Prestgaard, Erik Edvard; Mariampillai, Julian Eek; Engeseth, Kristian; Erikssen, Jan Emil; Bodegard, Johan & Liestøl, Knut [Show all 10 contributors for this article] (2018). Change in Cardiorespiratory Fitness and Risk of Stroke and Death. Stroke. ISSN 0039-2499. 50, p. 155–161. doi: 10.1161/STROKEAHA.118.021798.

View all works in Cristin

• Kreutz, Reinhold; Brunström, Mattias; Burnier, Michel; Grassi, Guido; Januszewicz, Andrzej & Kjeldsen, Sverre [Show all 10 contributors for this article] (2024). Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern. Journal of Hypertension. ISSN 0263-6352. 42(6), p. 966–967. doi: 10.1097/HJH.0000000000003735.
• Kjeldsen, Sverre & Grassi, Guido (2024). The role of β-blockers in medical treatment. Current Medical Research and Opinion. ISSN 0300-7995. 40(1), p. 1–2. doi: 10.1080/03007995.2024.2324138.
• Kjeldsen, Sverre; Egan, Brent M.; Burnier, Michel; Narkiewicz, Krzysztof; Kreutz, Reinhold & Mancia, Giuseppe (2024). Highlights of the 2023 European Society of Hypertension Guidelines: what has changed in the management of hypertension in patients with cardiac diseases? Blood Pressure. ISSN 0803-7051. 33(1). doi: 10.1080/08037051.2024.2329571.
• Mancia, Giuseppe & Kjeldsen, Sverre (2023). Randomized Clinical Outcome Trials in Hypertension. Hypertension. ISSN 0194-911X. 81(1), p. 17–23. doi: 10.1161/HYPERTENSIONAHA.123.21725.
• Kjeldsen, Sverre; Mariampillai, Julian Eek & Høieggen, Aud (2023). Uric acid and left ventricular mass in prediction of cardiovascular risk-New insight from the URRAH study . European journal of internal medicine. ISSN 0953-6205. 114, p. 45–46. doi: 10.1016/j.ejim.2023.05.016.
• Mariampillai, Julian Eek & Kjeldsen, Sverre (2023). Real-world data show the effect of statins in primary prevention. European Journal of Preventive Cardiology (EJPC). ISSN 2047-4873. 30(17), p. 1881–1882. doi: 10.1093/eurjpc/zwad231.
• Mariampillai, Julian Eek; Halvorsen, Lene Vernås; Larstorp, Anne Cecilie Kjeldsen; Heimark, Sondre; Waldum-Grevbo, Bård & Kjeldsen, Sverre [Show all 10 contributors for this article] (2023). Diabetes og kronisk nyresykdom. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(12). doi: 10.4045/tidsskr.22.0822.
• Kjeldsen, Sverre; Burnier, Michel; Narkiewicz, Krzysztof; Kreutz, Reinhold & Mancia, Giuseppe (2023). Key questions regarding the SYMPLICITY HTN-3 trial. The Lancet. ISSN 0140-6736. 401(10385), p. 1336–1337. doi: 10.1016/S0140-6736(23)00340-9.
• Burnier, Michel; Brguljan, Jana; Algharably, Engi Abd Elhady; Kjeldsen, Sverre; Narkiewicz, Krzysztof & Egan, Brent [Show all 8 contributors for this article] (2023). Women’s health, cardiovascular risk and hypertension: the perspective still needs to improve. Blood Pressure. ISSN 0803-7051. 32(1). doi: 10.1080/08037051.2023.2193648.
• Kjeldsen, Sverre; Egan, Brent M.; Narkiewicz, Krzysztof; Kreutz, Reinhold; Burnier, Michel & Oparil, Suzanne [Show all 7 contributors for this article] (2023). TIME to face the reality about evening dosing of antihypertensive drugs in hypertension. Blood Pressure. ISSN 0803-7051. 32(1), p. 1–3. doi: 10.1080/08037051.2022.2142512.
• Kjeldsen, Sverre; Brunström, Mattias; Thomopoulos, Costas; Carlberg, Bo; Kreutz, Reinhold & Mancia, Giuseppe (2022). Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes. The Lancet Diabetes and Endocrinology. ISSN 2213-8587. 10(12). doi: 10.1016/S2213-8587(22)00312-6.
• Narkiewicz, Krzysztof; Kjeldsen, Sverre; Egan, Brent M.; Kreutz, Reinhold & Burnier, Michel (2022). Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure. Blood Pressure. ISSN 0803-7051. 31(1), p. 207–209. doi: 10.1080/08037051.2022.2107483.
• Egan, Brent M.; Kjeldsen, Sverre; Narkiewicz, Krzysztof; Kreutz, Reinhold & Burnier, Michel (2022). Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood Pressure. ISSN 0803-7051. 31(1), p. 164–168. doi: 10.1080/08037051.2022.2095254.
• Halvorsen, Lene Vernås; Gognstad, Stine; Søraas, Camilla Lund; Ågnes, Camilla; Hjørnholm, Ulla & Kjær, Vibeke Norheim [Show all 21 contributors for this article] (2022). Implications of CYP2D6 polymorphisms for therapeutic drug monitoring in patients with hypertension. Journal of Hypertension. ISSN 0263-6352. 40. doi: 10.1097/01.hjh.0000838764.61491.a8.
• Mariampillai, Julian Eek; Kjeldsen, Sverre; Gjesdal, Knut Tjøl & Skretteberg, Torger (2022). Blood pressure during moderate or maximal exercise: hardly two sides of the same coin. Journal of Hypertension. ISSN 0263-6352. 40(6), p. 1243–1244. doi: 10.1097/HJH.0000000000003121.
• Kjeldsen, Sverre; Zachs, Eran S.; Stokke, Ildri Maria; Wachtell, Kristian; Hille, Darcy A. & Høieggen, Aud [Show all 10 contributors for this article] (2022). Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypersensitive patients. Journal of Hypertension. ISSN 0263-6352. 40, p. e3–e3. doi: 10.1097/01.hjh.0000835312.59915.7b.
• Kjeldsen, Sverre; Egan, Brent M.; Narkiewicz, Krzysztof; Kreutz, Reinhold; Burnier, Michel & Oparil, Suzanne (2022). Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure. ISSN 0803-7051. 31(1), p. 125–128. doi: 10.1080/08037051.2022.2083578.
• Burnier, Michel; Kjeldsen, Sverre; Narkiewicz, Krzysztof; Egan, Brent & Kreutz, Reinhold (2022). Hypertension management during the COVID-19 pandemic: what can we learn for the future? Blood Pressure. ISSN 0803-7051. 31(1), p. 47–49. doi: 10.1080/08037051.2022.2058909.
• Burnier, Michel & Kjeldsen, Sverre (2022). A 30th anniversary and a glimpse of the future. Blood Pressure. ISSN 0803-7051. 31(1), p. 1–3. doi: 10.1080/08037051.2021.2021638.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2021). Better drug adherence improves blood pressure control and lowers cardiovascular disease outcomes–from single pill combinations to monitoring of a nationwide health insurance database. Blood Pressure. ISSN 0803-7051. 30(3), p. 143–144. doi: 10.1080/08037051.2021.1917192.
• Burnier, Michel; Kjeldsen, Sverre; Narkiewicz, Krzysztof & Oparil, Suzanne (2021). Cuff-less measurements of blood pressure: are we ready for a change? Blood Pressure. ISSN 0803-7051. 30(4), p. 205–207. doi: 10.1080/08037051.2021.1956178.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2021). Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Pressure. ISSN 0803-7051. 30(1), p. 1–3. doi: 10.1080/08037051.2021.1862483.
• Gjesdal, Knut & Kjeldsen, Sverre (2021). Fusk og feil i forskning og forskningsformidling. Indremedisineren. ISSN 1891-1617. p. 54–57.
• Kjeldsen, Sverre E.; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2021). The five RADIANCE-HTN and SPYRAL-HTN randomised studies suggest that the BP lowering effect of RDN corresponds to the effect of one antihypertensive drug. Blood Pressure. ISSN 0803-7051. doi: 10.1080/08037051.2021.1995975.
• Kreutz, Reinhold; Kjeldsen, Sverre E. & Mancia, Giuseppe (2021). Why we do not need a single independent international hypertension clinical practice guideline. Journal of Hypertension. ISSN 0263-6352. 39(11), p. 2125–2127. doi: 10.1097/HJH.0000000000002940.
• Narkiewicz, Krzysztof; Burnier, Michel; Kjeldsen, Sverre & Oparil, Suzanne (2021). Combining proteomics, home blood pressure telemonitoring and patient empowerment to improve cardiovascular and renal protection. Blood Pressure. ISSN 0803-7051. 30(5), p. 267–268. doi: 10.1080/08037051.2021.1975878.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). Was it optimal to drop a diuretic as a first-line choice of drug treatment in the 2020 International Society of Hypertension Guidelines? Blood Pressure. ISSN 0803-7051. 29(6), p. 341–343. doi: 10.1080/08037051.2020.1838766.
• Kreutz, Reinhold; Kjeldsen, Sverre; Burnier, Michel; Narkiewicz, Krzysztof; Oparil, Suzanne & Mancia, Giuseppe (2020). Disregard the reported data from the HYGIA project: blood pressure medication not to be routinely dosed at bedtime. Journal of Hypertension. ISSN 0263-6352. 38(11), p. 2144–2145. doi: 10.1097/HJH.0000000000002671.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). The International Society of Hypertension Guidelines 2020–a new drug treatment recommendation in the wrong direction? Blood Pressure. ISSN 0803-7051. 29(5), p. 264–266. doi: 10.1080/08037051.2020.1806494.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). Intensive systolic blood pressure control and prevention of new onset atrial fibrillation in the SPRINT study: is the association really controversial? Blood Pressure. ISSN 0803-7051. 29(4), p. 199–201. doi: 10.1080/08037051.2020.1782595.
• Kreutz, Reinhold; Kjeldsen, Sverre; Burnier, Michel; Narkiewicz, Krzysztof; Oparil, Suzanne & Mancia, Giuseppe (2020). Blood pressure medication should not be routinely dosed at bedtime. We must disregard the data from the HYGIA project. Blood Pressure. ISSN 0803-7051. 29(3), p. 135–136. doi: 10.1080/08037051.2020.1747696.
• Kjeldsen, Sverre & Os, Ingrid (2020). Poor reproducibility of masked and white coat uncontrolled hypertension: Important new information on MUCH and WUCH. European Heart Journal. ISSN 0195-668X. 41(16), p. 1572–1574. doi: 10.1093/eurheartj/ehz703.
• Burnier, Michel; Kjeldsen, Sverre; Narkiewicz, Krzysztof & Oparil, Suzanne (2020). How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers. Blood Pressure. ISSN 0803-7051. 29(2), p. 68–69. doi: 10.1080/08037051.2020.1726101.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2020). The Health Outcomes Prevention and Evaluation 4 (HOPE 4) project: A successful community-based intervention to lower cardiovascular risk in people with hypertension. Blood Pressure. ISSN 0803-7051. 29(1), p. 1–2. doi: 10.1080/08037051.2020.1707440.
• Kjeldsen, Sverre (2019). Hypertension and associated cardiovascular risk factors in Romania. Revista română de cardiologie. ISSN 1220-658X. 29(4), p. 556–557.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). Systolic blood pressure control prevents cognitive decline and slows development of white matter lesions in the brain: the SPRINT MIND study outcomes. Blood Pressure. ISSN 0803-7051. 28(6), p. 356–357. doi: 10.1080/08037051.2019.1678261.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). The PARAGON-Heart failure trial–another disappointment for heart failure patients with hypertension and preserved ejection fraction. Blood Pressure. ISSN 0803-7051. 28(5), p. 276–278. doi: 10.1080/08037051.2019.1664717.
• Kjeldsen, Sverre & Os, Ingrid (2019). Are people with masked hypertension adherent to their antihypertensive medication? Hypertension. ISSN 0194-911X. 74(3), p. 497–498. doi: 10.1161/HYPERTENSIONAHA.119.13350.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). The PARAGON Heart Failure trial–ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction. Blood Pressure. ISSN 0803-7051. 28(4), p. 215–216. doi: 10.1080/08037051.2019.1625523.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). Need for multiple risk reduction strategies in clinical trials enrolling high risk patients - FOURIER investigating PCSK-9 inhibitor to lower cholesterol revisited. Blood Pressure. ISSN 0803-7051. 28(3), p. 144–145. doi: 10.1080/08037051.2019.1614278.
• Kjeldsen, Sverre; Atar, Dan & von Lueder, Thomas Gero (2019). Angiotensin receptor neprilysin inhibition for the treatment of hypertension: The neglected child in cardiovascular pharmacotherapy. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 5(2), p. 122–123. doi: 10.1093/ehjcvp/pvz005.
• Kjeldsen, Sverre; Fadl Elmula, Fadl Elmula M. & Persu, Alexandre (2019). Future of Renal Sympathetic Denervation in the Treatment of Hypertension. Journal of the American College of Cardiology. ISSN 0735-1097. 73(13), p. 1643–1645. doi: 10.1016/j.jacc.2019.02.008.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2019). Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension? Blood Pressure. ISSN 0803-7051. 28(2), p. 75–76. doi: 10.1080/08037051.2019.1584975.
• Burnier, Michel; Narkiewicz, Krzysztof; Kjeldsen, Sverre & Oparil, Suzanne (2019). New data on antihypertensive drugs and risk of cancer: should we worry? Blood Pressure. ISSN 0803-7051. 28(1), p. 1–3. doi: 10.1080/08037051.2019.1568182.
• Kjeldsen, Sverre & Mancia, Giuseppe (2019). Unattended automated office vs. ambulatory blood pressure in people with high cardiovascular risk: implications for understanding the SPRINT results. Journal of Hypertension. ISSN 0263-6352. 37(1), p. 6–8. doi: 10.1097/HJH.0000000000001874.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2018). 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension. Blood Pressure. ISSN 0803-7051. 27(6). doi: 10.1080/08037051.2018.1530564.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2018). Intensive blood pressure lowering prevents mild cognitive impairment and possible dementia and slows development of white matter lesions in brain: the SPRINT Memory and Cognition IN Decreased Hypertension (SPRINT MIND) study. Blood Pressure. ISSN 0803-7051. 27(5), p. 247–248. doi: 10.1080/08037051.2018.1507621.
• Kjeldsen, Sverre; Narkiewicz, Krzysztof; Burnier, Michel & Oparil, Suzanne (2018). Renal denervation achieved by endovascular delivery of ultrasound in RADIANCE-HTN SOLO or by radiofrequency energy in SPYRAL HTN-OFF and SPYRAL-ON lowers blood pressure. Blood Pressure. ISSN 0803-7051. 27(4), p. 185–187. doi: 10.1080/08037051.2018.1486178.
• Kjeldsen, Sverre; Mariampillai, Julian Eek & Nilsson, Peter M. (2018). Optimal blood pressure target in diabetic and nondiabetic hypertensive patients. Circulation Research. ISSN 0009-7330. 123(5), p. 528–530. doi: 10.1161/CIRCRESAHA.118.312763.
• Mehlum, Maria Hollund; Liestøl, Knut; Kjeldsen, Sverre & Berge, Eivind (2018). Response to letters from Torp-Pedersen and colleagues and de Courson and colleagues. European Heart Journal. ISSN 0195-668X. 39(47), p. 4221–4221. doi: 10.1093/eurheartj/ehy605.

View all works in Cristin